232 related articles for article (PubMed ID: 23524581)
21. Mechanisms of resistance to cabazitaxel.
Duran GE; Wang YC; Francisco EB; Rose JC; Martinez FJ; Coller J; Brassard D; Vrignaud P; Sikic BI
Mol Cancer Ther; 2015 Jan; 14(1):193-201. PubMed ID: 25416788
[TBL] [Abstract][Full Text] [Related]
22. Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines.
Ling YH; Jiang JD; Holland JF; Perez-Soler R
Mol Pharmacol; 2002 Sep; 62(3):529-38. PubMed ID: 12181429
[TBL] [Abstract][Full Text] [Related]
23. Taxanes, microtubules and chemoresistant breast cancer.
McGrogan BT; Gilmartin B; Carney DN; McCann A
Biochim Biophys Acta; 2008 Apr; 1785(2):96-132. PubMed ID: 18068131
[TBL] [Abstract][Full Text] [Related]
24. miR-130a activates apoptotic signaling through activation of caspase-8 in taxane-resistant prostate cancer cells.
Fujita Y; Kojima T; Kawakami K; Mizutani K; Kato T; Deguchi T; Ito M
Prostate; 2015 Oct; 75(14):1568-78. PubMed ID: 26074357
[TBL] [Abstract][Full Text] [Related]
25. Structural insight into the stabilization of microtubules by taxanes.
Prota AE; Lucena-Agell D; Ma Y; Estevez-Gallego J; Li S; Bargsten K; Josa-Prado F; Altmann KH; Gaillard N; Kamimura S; Mühlethaler T; Gago F; Oliva MA; Steinmetz MO; Fang WS; Díaz JF
Elife; 2023 Mar; 12():. PubMed ID: 36876916
[TBL] [Abstract][Full Text] [Related]
26. Relationship between the structures of taxane derivatives and their microtubule polymerization activity.
Hidaka M; Koga T; Kiyota H; Horiguchi T; Shi QW; Hirose K; Uchida T
Biosci Biotechnol Biochem; 2012; 76(2):349-52. PubMed ID: 22313785
[TBL] [Abstract][Full Text] [Related]
27. Tissue inhibitor of metalloproteinase-1 protects MCF-7 breast cancer cells from paclitaxel-induced apoptosis by decreasing the stability of cyclin B1.
Wang T; Lv JH; Zhang XF; Li CJ; Han X; Sun YJ
Int J Cancer; 2010 Jan; 126(2):362-70. PubMed ID: 19609944
[TBL] [Abstract][Full Text] [Related]
28. Farnesyltransferase inhibitors reverse taxane resistance.
Marcus AI; O'Brate AM; Buey RM; Zhou J; Thomas S; Khuri FR; Andreu JM; Díaz F; Giannakakou P
Cancer Res; 2006 Sep; 66(17):8838-46. PubMed ID: 16951201
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents.
Fojo T; Menefee M
Ann Oncol; 2007 Jul; 18 Suppl 5():v3-8. PubMed ID: 17656560
[TBL] [Abstract][Full Text] [Related]
30. Taxanes convert regions of perturbed microtubule growth into rescue sites.
Rai A; Liu T; Glauser S; Katrukha EA; Estévez-Gallego J; Rodríguez-García R; Fang WS; Díaz JF; Steinmetz MO; Altmann KH; Kapitein LC; Moores CA; Akhmanova A
Nat Mater; 2020 Mar; 19(3):355-365. PubMed ID: 31819210
[TBL] [Abstract][Full Text] [Related]
31. Comparison of cell death-inducing effect of novel taxane SB-T-1216 and paclitaxel in breast cancer cells.
Kovár J; Ehrlichová M; Smejkalová B; Zanardi I; Ojima I; Gut I
Anticancer Res; 2009 Aug; 29(8):2951-60. PubMed ID: 19661300
[TBL] [Abstract][Full Text] [Related]
32. Repurposing of phentolamine as a potential anticancer agent against human castration-resistant prostate cancer: A central role on microtubule stabilization and mitochondrial apoptosis pathway.
Ho CH; Hsu JL; Liu SP; Hsu LC; Chang WL; Chao CC; Guh JH
Prostate; 2015 Sep; 75(13):1454-66. PubMed ID: 26180030
[TBL] [Abstract][Full Text] [Related]
33. Enhanced microtubule binding and tubulin assembly properties of conformationally constrained paclitaxel derivatives.
Shanker N; Kingston DG; Ganesh T; Yang C; Alcaraz AA; Geballe MT; Banerjee A; McGee D; Snyder JP; Bane S
Biochemistry; 2007 Oct; 46(41):11514-27. PubMed ID: 17892304
[TBL] [Abstract][Full Text] [Related]
34. Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules.
Hari M; Loganzo F; Annable T; Tan X; Musto S; Morilla DB; Nettles JH; Snyder JP; Greenberger LM
Mol Cancer Ther; 2006 Feb; 5(2):270-8. PubMed ID: 16505100
[TBL] [Abstract][Full Text] [Related]
35. Paclitaxel and docetaxel in prostate cancer.
Obasaju C; Hudes GR
Hematol Oncol Clin North Am; 2001 Jun; 15(3):525-45. PubMed ID: 11525295
[TBL] [Abstract][Full Text] [Related]
36. Lx2-32c, a novel taxane derivative, exerts anti-resistance activity by initiating intrinsic apoptosis pathway in vitro and inhibits the growth of resistant tumor in vivo.
Zhou Q; Li Y; Jin J; Lang L; Zhu Z; Fang W; Chen X
Biol Pharm Bull; 2012; 35(12):2170-9. PubMed ID: 23207769
[TBL] [Abstract][Full Text] [Related]
37. A cell-based pharmacokinetics assay for evaluating tubulin-binding drugs.
Wang Y; Liu J; Zhang J; Wang L; Chan J; Wang H; Jin Y; Yu L; Grainger DW; Ying W
Int J Med Sci; 2014; 11(5):479-87. PubMed ID: 24688312
[TBL] [Abstract][Full Text] [Related]
38. EphrinB1: novel microtubule associated protein whose expression affects taxane sensitivity.
Colbert PL; Vermeer DW; Wieking BG; Lee JH; Vermeer PD
Oncotarget; 2015 Jan; 6(2):953-68. PubMed ID: 25436983
[TBL] [Abstract][Full Text] [Related]
39. Molecular mechanism of antitumor activity of taxanes in lung cancer (Review).
Zhao J; Kim JE; Reed E; Li QQ
Int J Oncol; 2005 Jul; 27(1):247-56. PubMed ID: 15942666
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of a Covalent Microtubule Stabilizer in Taxane-Resistant Ovarian Cancer Models.
Yee SS; Risinger AL
Molecules; 2021 Jul; 26(13):. PubMed ID: 34279417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
